Retatrutide TRIUMPH 4 Osteoarthritis WOMAC Score 67 Percent Pain Reduction Mechanism

Retatrutide in the TRIUMPH-4 trial delivered impressive results for knee osteoarthritis patients, achieving up to a 67 percent pain reduction in WOMAC scores[2] through its weight loss mechanism. Patients on the 12 mg dose lost 28.7 percent of body weight over 68 weeks,[1][2] far outperforming placebo. This retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism highlights how shedding pounds eases joint stress, offering hope for better pain management. Note: Results based on topline data announced December 11, 2025[2]; full peer-reviewed publication pending.

Introduction to Retatrutide TRIUMPH 4 Osteoarthritis Trial

The TRIUMPH-4 trial tests retatrutide as a new option for people with knee osteoarthritis and obesity. It focuses on pain relief measured by the WOMAC score, a tool doctors use to track osteoarthritis symptoms like pain, stiffness, and function. Early results show big improvements, making it a key study in this field.

What is Retatrutide TRIUMPH 4 Osteoarthritis WOMAC Score?

Retatrutide TRIUMPH 4 osteoarthritis WOMAC score tracks pain on a scale from 0 to 20, where lower scores mean less pain. In the trial, patients saw reductions of up to 4.5 points,[2] equating to about 67 percent improvement from baseline levels around 6. This change is clinically meaningful, as drops over 4 points often lead to real-life benefits like easier walking.

The study (NCT05931367)[1] enrolled adults with knee OA and high BMI, without diabetes. It used retatrutide doses of 9 mg and 12 mg weekly via injection,[1] alongside diet and exercise.

Breakdown of 67 Percent Pain Reduction Claim

The 67 percent pain reduction comes from analyzing WOMAC pain subscale changes, reported as around 67-76 percent in topline data.[2] For context, baseline pain averaged near 6 points; retatrutide dropped it by 4.5 points.[2] This beats placebo, where changes were minimal.

Post-hoc analysis showed 12.5 percent of retatrutide users became pain-free, versus 4.2 percent on placebo.[2] These gains tie directly to the retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism.

Why This Matters for Knee Osteoarthritis Patients

Knee OA affects millions, worsened by extra weight that stresses joints. Retatrutide offers dual benefits: massive weight loss plus pain relief. Patients could move better, reducing reliance on painkillers or surgery.

For those with BMI over 35, this trial brings real hope. It shows obesity treatments can target OA symptoms head-on, aligning with the retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism.

What is Retatrutide and Its Mechanism of Action?

Retatrutide is an investigational drug from Eli Lilly,[4] a triple hormone agonist.[3] It mimics three gut hormones to control hunger, blood sugar, and energy use. Unlike single or dual agonists like semaglutide, it hits GIP, GLP-1, and glucagon receptors.[3]

Triple Hormone Receptor Agonist: GIP, GLP-1, and Glucagon

GIP boosts insulin after meals and curbs appetite. GLP-1 slows digestion and signals fullness. Glucagon burns fat and raises energy use.

Together, they drive deep weight loss—up to 28.7 percent in TRIUMPH-4.[1][2] This powers the retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism. See details in Lilly's press release.

How Weight Loss Drives Osteoarthritis Pain Relief

Extra weight loads knees with pounds of force per step. Losing 28.7 percent body weight (71 pounds average) cuts this load sharply. Less pressure means less inflammation and pain, explaining the WOMAC improvements.

Studies link 10 percent weight loss to 50 percent pain drop in OA. Retatrutide doubles that impact, making it a standout for joint health.

Retatrutide Doses in TRIUMPH-4: 9mg vs 12mg

Both doses worked well: 26.4 percent loss at 9 mg, 28.7 percent at 12 mg.[2] Higher dose gave slightly better WOMAC gains. Dosing starts low and ramps up to reduce side effects, improving tolerability over time.

TRIUMPH-4 Trial Design and Patient Population

TRIUMPH-4 is a Phase 3 study evaluating retatrutide for obesity-related knee OA.[1] It's part of Lilly's bigger TRIUMPH program with over 5,800 participants.[4]

Phase 3 Study Overview: NCT05931367

This 68-week trial[1] randomized patients 1:1:1 to 9 mg, 12 mg retatrutide, or placebo.[1] Everyone followed diet and exercise plans. Co-primary endpoints: weight change and WOMAC pain score.[1]

68-Week Double-Blind Placebo-Controlled Design

Double-blind means neither patients nor doctors knew who got what. This prevents bias. At week 68, all endpoints met significance versus placebo.

Baseline Characteristics: Obesity, BMI 40.4 kg/m², Knee OA

Patients averaged 112.7 kg (248 lbs), BMI 40.4.[1] All had moderate-to-severe knee OA pain. No diabetes ensured focus on obesity-OA link. This group reflects real-world patients struggling with weight and joint pain.

Key Efficacy Results: Weight Loss and WOMAC Scores

Results crushed expectations. Retatrutide hit both primary goals with room to spare. For comparison, see TRIUMPH-1 weight loss results.

28.7% Body Weight Loss at 12mg Dose

High weight loss drove joint benefits:

Dose	% Body Weight Loss	Absolute Loss (avg.)
12 mg	28.7%	71.2 lbs
9 mg	26.4%	~59.8 lbs
Placebo	2.1%	Minimal

High rates hit 25-35% loss thresholds, rare in prior trials.

WOMAC Pain Score: Up to 4.5 Points (75.8% Reduction from Baseline)

WOMAC pain fell 4.5 points (67-75.8% drop).[2] This is the core of retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism. Function scores improved too, with significant gains across subscales.

Physical Function Improvements and Pain-Free Rates (12.5% vs 4.2%)

Physical function WOMAC subscales rose significantly. 12.5% on retatrutide reported zero pain, vs. 4.2% placebo.[2] Patients walked farther with less stiffness.

Bonus: Cardio perks like 14 mmHg blood pressure drop, lower cholesterol, triglycerides, and inflammation (hsCRP).[2]

Retatrutide TRIUMPH 4 Osteoarthritis WOMAC Score 67 Percent Pain Reduction Mechanism Explained

The magic isn't direct on joints—it's indirect via weight. Here's how it unfolds, central to the retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism.

Indirect Mechanism: Mechanical Load Reduction via Weight Loss

Each pound lost unloads 4 pounds off knees. 71-pound loss slashes force dramatically. This eases cartilage wear, swelling, and nerve pain, boosting WOMAC scores by 67 percent.

Metabolic tweaks like lower inflammation (hsCRP drop) and better glucose control add layers of relief. Weight loss also reduces fat-related cytokines that inflame joints.

Cardiovascular Benefits Supporting Joint Health

Lower BP, cholesterol, and triglycerides improve blood flow to joints. Healthier vessels mean better repair, amplifying pain relief. These changes support long-term OA management.

Comparison to Placebo and Clinical Significance

Placebo saw tiny changes; retatrutide transformed lives. A 4.5-point WOMAC drop matches surgery-level gains for some. Clinicians view drops >2 points as moderate, >4 as large.

Safety Data and Side Effects from TRIUMPH-4

Safety mirrored other weight-loss drugs like GLP-1s. Most issues were mild, early-onset, and faded. No new safety signals emerged. Topline data; full analysis pending.

Common GI Side Effects: Nausea, Diarrhea, Vomiting

Gastrointestinal effects were dose-dependent:

• Nausea: Most common (early weeks), resolved in most
• Diarrhea/vomiting: 10-20% higher than placebo
• Constipation/decreased appetite: Aided adherence and loss

Tips: Slow titration, hydration, and anti-nausea meds helped retention.

Dysesthesia Incidence (Up to 20.9% at 12mg)

Dysesthesia (skin tingling or numbness, often oral/peripheral) hit 20.9% at 12 mg,[2] mostly mild/transient. It rarely caused quits (<1%). Learn more on retatrutide dysesthesia side effects. Mechanism may tie to glucagon effects; monitoring advised.

Discontinuation Rates: 12-18% vs 4% Placebo, BMI Correlation

Overall discontinuations:

Group	All-Cause	Adverse Events
9 mg	12%	8.8-12%
12 mg	18%	12.1%
Placebo	4%	4.8%

Higher in lower BMI due to rapid loss intensity. See details on retatrutide phase 3 discontinuations and BMI correlation. Serious events low across arms.

Clinical Trial Status, Legal Status, and FDA Approval Timeline

TRIUMPH-4 wrapped with positive topline data. Note: Dates future-oriented based on announcements.

Topline Results Announced December 11, 2025

Full details coming at conferences and journals. 7 more TRIUMPH readouts in 2026.[4]

Investigational Status: No FDA Approval Yet

Retatrutide is experimental. Check is retatrutide FDA approved.

TRIUMPH Program: 7 More Phase 3 Readouts in 2026

Includes CVD, OSA nests. Track via retatrutide FDA approval tracker.

Future Implications for Retatrutide in Osteoarthritis Treatment

Retatrutide could reshape OA care, especially with obesity. Basket design links it to OSA, CVD outcomes.

Role in TRIUMPH Program Basket Trials (OSA, CVD)

TRIUMPH nests OA with OSA, CVD. See TRIUMPH trials for OSA and OA. Multi-indication data strengthens approval case.

Potential for Knee OA Approval and Maintenance Dosing

4 mg maintenance keeps weight off long-term. Fits OA ongoing use, preventing regain. Details on 4mg maintenance dose strategy. Could pair with PT or NSAIDs.

Comparisons to Existing Weight Loss Therapies

Therapy	Max Weight Loss	OA Pain Impact
Semaglutide	15-20%	Moderate
Tirzepatide	20-25%	Good
Retatrutide	28.7%	Superior

Deeper loss means bigger joint relief. Potential label for obesity + OA complications.

Conclusion: Retatrutide's Promise for OA Pain Management

Retatrutide shows strong potential via its targeted weight loss approach.

Summary of 67% Pain Reduction Mechanism

Retatrutide TRIUMPH 4 osteoarthritis WOMAC score 67 percent pain reduction mechanism relies on epic weight loss unloading knees—28.7% drop plus metabolic wins delivered 4.5-point WOMAC gains (67-76% from baseline).[2]

What Patients Should Know Before Availability

Talk to doctors; not yet approved. Lifestyle changes boost results. Monitor for GI effects; BMI influences tolerance.

Stay Updated on Full TRIUMPH-4 Publication

Watch for peer-reviewed papers in 2026. This could change OA treatment paradigms.

References

1. TRIUMPH-4 Trial Record (NCT05931367)
2. Lilly TRIUMPH-4 Topline Results Press Release
3. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (NEJM)
4. Lilly Announces Phase 3 TRIUMPH Program Initiation